Targeted FLT3l immunoconjugates and methods of use

TW202633903APending Publication Date: 2026-08-16F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114143971
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-12
Filing Date
2025-11-11
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001072969_001
    Figure TWG2TA001072969_001
  • Figure TWG2TA001072969_002
    Figure TWG2TA001072969_002
  • Figure TWG2TA001072969_003
    Figure TWG2TA001072969_003
Patent Text Reader

Abstract

The invention provides an immunoconjugate comprising a mutant FLT3L cytokine and a targeted at least bivalent antibody that binds to CLEC9A, wherein the affinity of the mutant FLT3L is reduced as compared to the wild type FLT3L as measured by surface plasmon resonance (SPR) at 25°Canti and methods of using the same.
Need to check novelty before this filing date? Find Prior Art